Introduction Perforator veins (PVs) play an important role in the development of chronic venous insufficiency and ulceration. Procedures to eliminate incompetence and reflux in PV may include open surgery, subfascial endoscopic surgery, intravenous ablation techniques and sclerotherapy. With the aim of filling the evidence gap, this is a protocol for a systematic review that will assess the effects of any form of intervention for the treatment of pathologic PVs of the lower limbs in patients with chronic venous disease. Methods and analysis Systematic searches will be carried out in MEDLINE, EMBASE, Cochrane CENTRAL, IBECS and LILACS databases at a minimum without date or language restrictions for relevant randomised controlled trials (RCTs) and quasi-RCTs (trials in which the method of allocation is not truly random). In addition, a search will also be carried out in the WHO International Clinical Trials Registry Platform, in the clinical trial registries of ClinicalTrials. gov and in the grey literature source OpenGrey. eu. The RCT and quasi-RCT comparison techniques isolated or in combination for treating PVs will be considered. Three review authors will independently perform data extraction and quality assessments of data from included studies, and any disagreements will be resolved by discussion. The primary outcomes will be wound healing and pain. Secondary outcomes will include oedema, adverse events, recurrence or recanalisation, quality of life and economic aspects. The Cochrane handbook will be used for guidance. If the results are not appropriate for a meta-analysis in RevManV.5 software (eg, if the data have considerable heterogeneity and are drawn from different comparisons), a descriptive analysis will be performed. Ethics and dissemination Ethics committee approval is not necessary. We intend to update the public registry used in this review, report any important protocol amendments and publish the results in a widely accessible journal. PrOsPErO registration number CRD42018092974
IntrOduCtIOn
Perforator veins (PVs) play an important role in the development of chronic venous insufficiency and ulceration 1 and are a significant factor in the determination of chronic venous disease severity. 2 Since 1916, when Homans made the first description, PVs have been implicated in the development of venous ulcers. 3 Currently, there is no established preferred procedure for the treatment of pathologic perforator veins (PPVs) in patients designated as clinical class 2 and clinical class 3 of the Clinical Aetiologic Anatomic Pathophysiologic (CEAP) classification 4 ; however, patients with venous ulcers should receive attention for the treatment of PVs in cases of failure to treat truncal surface reflux. 5 Clinical practice guidelines of the Society for Vascular Surgery (SVS) and the American Venous Forum (AVF) recommend the treatment of PVs with diameters >3.5 mm and reflux time >0.5 s located near healed or active venous ulcers. 6 7 However, this recommendation is weak and, at most, obtains moderate evidence certainty because it is strengths and limitations of this study ► Well-accepted standards for the conduct and reporting of systematic reviews will be followed. ► The systematic approach (Cochrane handbook and GRADE approach) for summarising the current available evidence on the effects of various types of interventions for the treatment of incompetent perforator veins will strengthen the review. ► This review may allow future contributions to high-quality guidelines and better decision-making on the choice of treatment modality for the segment of the population with chronic venous disease, given that the range of clinical manifestations and treatment options make this type of disease a challenge. ► Since only randomised-controlled trials (RCTs) or quasi-RCTs will be included, some old comparisons (eg, with intra-operative reflux visualisation) may have little available evidence.
Open access based on randomised controlled trials (RCTs) with small samples and systematic reviews (SRs) with serious methodological biases. For instance, some SRs filtered data by publication language and other SRs meta-analysed RCTs with case series without a justified reason. 6 7 The most recent SVS/AVF document about the treatment of chronic venous diseases recommends the selective treatment of incompetent PVs in patients with simple varicose veins (CEAP C2). However, its recommendation is also based on small RCTs or SRs with serious methodological issues. The European Society for Vascular Surgery practice guidelines lack robust evidence assessing the treatment of PPVs but define PPVs as a reflux time greater than 0.35 s. 8 Procedures to eliminate incompetence and reflux in PVs may use surgical ligation, subfascial endoscopic surgery, intravenous ablation techniques and sclerotherapy. 3 With improvements in technology, traditional open surgical options for the disconnection of PVs have been supplanted by minimally invasive techniques in practice, even without robust evidence. Regardless of the method used, occlusion of a PV is useful for wound healing and venous insufficiency with minimal morbidity. 5 Therefore, there is an interest in comparing surgical options for the treatment of incompetent PVs. Although the rates of PV closure initially reported for percutaneous thermal ablation ranged from 60% to 80%, vein recanalisation and the formation of new incompetent veins have also been reported. 1 Ultrasound-guided foam sclerotherapy has shown promise in the closure of PVs and in wound healing but with varying success rates and associated possible associate adverse effects (eg, deep vein thrombosis, pulmonary embolism and death). 9 10 Evidence of the benefits of saphenous ablation has been growing; however, there is no high-quality evidence that addresses the treatment of incompetent PVs. 1 11-13 With the aim of filling the evidence gap, this is a protocol for an SR and meta-analysis that will assess the effects of any form of intervention, isolated or in combination, for the treatment of PPVs of the lower limbs in patients with chronic venous disease, a CEAP clinical classification of 0-6, with clinical and objective evidence of PPVs.
MEthOds
This protocol is prospectively registered in the international prospective register of SRs PROSPERO database (CRD42018092974) and is based on the Cochrane handbook of interventions reviews.
14 In addition, the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Protocols are used to report this protocol. 15 types of studies RCTs and quasi-RCTs will be accepted; thus, other study designs will be excluded for the purpose of this review. A quasi-RCT is a trial in which participants are allocated to different groups using a method of allocation that is not truly random (eg, date of birth, medical record number or the order in which people were recruited). 16 types of participants While there are recommendations for the treatment of PPVs in patients with CEAP C5-6, the evidence favouring PPVs treatment in those with CEAP C0-4 is more sparse. 7 8 However, PPVs is recognised as an important risk factor for the determination of chronic venous disease severity. 2 Therefore, patients with chronic venous disease, a CEAP clinical classification 0-6, with clinical and objective evidence of PPVs and without any limits on age and gender will be considered. The diagnosis of PPVs will be considered valid only with at least one of the following objective evaluations: ► PV reflux on duplex ultrasound (DUS) (ie, reflux time of at least 0.35 s) with the patient in the erect position.
8
► PPVs on digital subtraction angiography (DSA) (ie, ascending or descending phlebography). 8 17 ► Intraoperative PV reflux. 17 An objectively confirmed diagnosis is essential for patient inclusion. Traditional clinical tests (eg, Trendelenburg and Perthes) will not be considered adequate because they have been shown to be inaccurate and have no place in the mapping of venous incompetence in general, particularly in the case of PPVs. 8 18 Other methods such as CT angiography, MRI or intravascular ultrasound are not routinely used for the diagnosis of PPVs and therefore will not be considered a valid method. 8 
types of interventions
We will study all the following techniques, isolated or in combination, for treating PV insufficiency: ► Non-operative therapy; for example, any treatment without direct intervention on the insufficient PV (eg, local wound care, phlebotonics 19 and compression therapy). ► Conventional surgery; for example, traditional treatment, which is open exposure and subfascial ligation of PPVs.
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► Subfascial endoscopic perforator surgery (SEPS) involving the endoscopic access and identification of PPVs and their ligation.
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► Minimally invasive vein surgery, which is performed percutaneously, with minimal anaesthesia, no incisions, and rarely requires hospital admission. 22 There are a variety of minimally invasive techniques and treatment modalities, including ultrasound-guided sclerotherapy and endovascular thermal ablation with laser or radiofrequency energy. These techniques can be performed in an office setting with local anaesthesia. 23 We will consider all of the following possible comparisons: ► Minimally invasive vein surgery (all types) versus conventional surgery. ► SEPS versus conventional surgery.
► Non-operative therapy versus conventional surgery. ► Any combination of the above treatments versus any combination.
types of outcome measures
Following the Cochrane recommendations, all the outcomes will be meaningful for decision makers, that is, clinicians, patients, the general public, administrators and policy makers. 24 Almost 80% of the general population may suffer from CEAP C1, and 30% may suffer from CEAP C2. Pain is the main symptom in venous disease, including PPVs. Pain is also a well-known contributor to decreasing quality of life. Only 1%-2% of these patients may develop an ulcer (CEAP C6). 8 25 While the treatment for PPVs also aims to reduce pain, all types of these surgical interventions may inflict pain as an adverse event. Therefore, pain and ulcer healing are the primary outcomes, and all other patient-relevant outcomes are listed as secondary. Open access
Primary outcomes

Manual search
The reference lists of all included studies and review articles will be searched for additional RCTs or quasiRCTs. Manufacturers and specialists in the field of phlebology will be contacted, mainly for further unpublished research. In addition, authors of identified trials will be asked about additional data from the included trials as well as for other additional studies.
selection of studies Three independent reviewers (MAMS, RLGF and LCUN) will evaluate the trials to determine if they are appropriate for inclusion. Any disagreement will be solved by discussion with the author's team (FMJ, RSC, SGJS and HJGN).
Full-text articles of potentially eligible studies will be analysed in detail, and then it will be decided which ones will be included; the reasons for study exclusion will be presented. Sufficient details on the selection process will be recorded, and the PRISMA flow diagram and tables will be filled in with the characteristics of the included and excluded studies. 15 
data extraction and management
The following data on the study characteristics and outcomes of the included studies will be extracted by three independent reviewers (MAMS, RLGF and LCUN) 14 :
► Methods: study design, total duration of the study and period of carryout, number and location of study centres, research setting, withdrawals and date of study. Participants: number, age parameters (ie, mean, range and so on), gender, the severity of the condition, diagnostic criteria and inclusion/exclusion criteria. ► Interventions: intervention, comparison, concomitant medications, and excluded medications. ► Outcomes: primary and secondary outcomes (the final outcomes reported and those planned) and time points reported. ► Notes: funding for trial and notable conflicts of interest of trial authors. One author (MAMS) will enter these data into Review Manager 5 software (RevMan 5), version 5.3, for statistical analysis. 31 If the results are not appropriate for a meta-analysis, a descriptive analysis will be performed.
Assessment of risk of bias in included studies
Three independent reviewers (MAMS, RLGF and LCUN) will assess the following risk of bias domains: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective outcome reporting and (7) other bias. Each of these domains will be graded as high, low or unclear risk of bias according to the Cochrane handbook.
14 Blinding will be considered separately for different key outcomes when necessary. When considering treatment effects, the risk of bias of the studies that contributed to that outcome will be taken into account.
Measures of treatment effect Dichotomous data will be analysed as risk ratio and continuous data with the same scales as the mean difference. A standardised mean difference will be used for continuous data with different scales. CI of 95% will be considered for all data.
unit of analysis issues Lower limbs will be the unit of analysis for all outcomes (eg, ulcer healing). Nevertheless, the participant will be the unit of analysis for other outcomes such as pain, mortality, adverse events, quality of life and length of hospitalisation. The intention-to-treat approach will be used.
Addressing missing data
We will contact the authors or sponsors of the included studies, either to verify details about methods and characteristics or to request missing numerical outcome data. Significant bias is not expected if both intervention groups have outcome data missing with reasons that are balanced and reported across groups. However, if the missing data have different implications in the compared groups, the studies will be considered to have a high risk of bias. The frequency (or risk) of outcomes has a direct influence on the potential impact of missing data in dichotomous outcomes studies, while the proportion of participants with missing data is directly related to the potential impact on continuous outcomes studies. 14 
Assessment of heterogeneity
The studies will be assessed for methodological and clinical heterogeneity using the I² statistic (where I 2 = [(Q− df)/Q] x 100%; Q = Χ 2 statistic; 'df'=degree of freedom). Meta-analyses will be conducted if, after these analyses, the studies are considered to have acceptable heterogeneity. We will analyse statistical heterogeneity by visual inspection of the forest plots if possible (ie, if more than 10 studies are included). As strict thresholds for interpretation of I 2 are not recommended, we will follow the rough guide for interpretation in the Cochrane handbook for SRs of interventions 32 :
► 0% to 40%: possibly not important. ► 30% to 60%: may represent moderate heterogeneity. ► 50% to 90%: may represent substantial heterogeneity. ► 75% to 100%: considerable heterogeneity. Heterogeneity stratification demonstrates the percent variability in the estimated effects resulting from heterogeneity rather than sampling error. 14 We will attempt to explain any substantial heterogeneity by performing subgroup analyses on the pre-specified groups and by examining the findings of the evaluation of publication bias.
Assessment of reporting biases
If there is an adequate number of studies (at least 10) for inclusion in a meta-analysis, the presence of publication bias and other types of reporting bias will be assessed using funnel plots.
Open access data synthesis We will synthesise qualitative information relative to methods, risk of bias, description of participants, and outcome measures and insert this information in the 'Characteristics of included studies' tables using the software RevMan 5, and a meta-analysis will be performed whenever it is feasible. 31 We will not include qualitative (non-randomised) studies in the review. We will use a fixed-effects model in a meta-analysis with very homogenous included studies, considering population, interventions, comparators and outcomes characteristics. Otherwise, we will use a random-effects model if at least substantial heterogeneity (I 2 of 50% or more) is identified, or if significant clinical differences regarding patients and interventions exist among included trials. 32 subgroup analysis and investigation of heterogeneity In the case of substantial heterogeneity, we will perform a subgroup analysis to explore possible causes. It will be carried out for participants' characteristics (eg, age, gender and race) and intervention characteristics (eg, type of treatment). We will attempt to contact the authors to obtain missing data when data are not available from the original publications.
sensitivity analysis A sensitivity analysis will be conducted to determine the impact of exclusion of quasi-RCTs or studies with an overall high risk of bias, which are those studies with a high risk of bias in at least one of the main domains in the risk of bias tool (generation of randomisation sequence, allocation concealment and blinding). 32 'summary of findings' table We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) software (GRADEpro) to generate a 'Summary of findings' table for each one of the outcomes to be analysed in this review. 35 Using the five GRADE criteria (study limitations, consistency of effect, imprecision, indirectness and publication bias), we will assess the quality of the body of evidence that made up the data for the meta-analyses of the pre-specified outcomes. 35 36 These criteria will be evaluated, and the table will be filled in by using the Cochrane recommendations, justifying any departures from the standard methods. 14 
Patient and public involvement
The research question was developed from the authors' experience treating patients with venous disease, associated with methodological knowledge and under the advisement of a patient group for the selection of the main patient-relevant outcomes. Patients were involved in the design of this protocol in the form of a discussion group to define the research question, for outcome selection and to ensure comprehension of the final manuscript. However, they did not contribute sufficiently to qualify as co-authors. We intend to include patients in all steps of this research as advisors and to maintain comprehensive language in the final text that will be appropriate for consumers. The final version of this review, with results, conclusions and any changes in the protocol, will be published in an accessible international journal; presented in related congresses, conferences and meetings; and sent to the offices of health policy makers.
Ethics and dissemination
We will not treat patients directly; therefore, ethics committee approval is not necessary because it is not a primary study. It is hoped that the authors of primary studies to be included in the analysis have already obtained such approval. We intend to update the public registry with this review in all phases of its execution, report any important protocol amendments and publish the results in a widely accessible journal.
Correction notice This article has been corrected since it was published online. Orcid Ids have been updated for the authors.
